Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

8.900 +0.050 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Arcturus Therapeutics's Earnings Outlook ↗
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying... 
Via Benzinga
News headline image
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics
Via Business Wire
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
News headline image
31 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
92 Biggest Movers From Friday ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Leadership Appointments
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT ↗
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
News headline image
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83 ↗
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
News headline image
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.